TABLE 3.
Baseline variables associated with opioid and cocaine use during treatment
| Variable | Opioid Use During Treatment | Cocaine Use During Treatment | ||||
|---|---|---|---|---|---|---|
| Opioid-negative urine samples % |
Unadjusted OR1 (95% CI3) |
Adjusted OR2 (95% CI3) |
Cocaine-negative urine samples % | Unadjusted OR1 (95% CI3) |
Adjusted OR2 (95% CI3) |
|
| Age | ||||||
| ≤38 | 72 | 1.17 (0.87–1.57) | 1.76 (1.27–2.45)6 | 69 | 1.09 (0.80–1.49) | 1.57 (1.10–2.25) |
| >38 | 77 | 72 | ||||
| Gender | ||||||
| Female | 76 | 1.11 (0.83–1.50) | 1.18 (0.80–1.73) | 73 | 1.10 (0.80–1.50) | 1.24 (0.83–1.87) |
| Male | 73 | 69 | ||||
| Race | ||||||
| African American | 73 | 1.35 (1.00–1.83) | 1.16 (0.82–1.63) | 68 | 1.59 (1.16–2.18) | 1.48 (1.04–2.11) |
| White | 77 | 75 | ||||
| Employment status | ||||||
| Employed | 80 | 1.68 (1.19–2.38) | 1.10 (0.75–1.62) | 80 | 2.18 (1.52–3.14) | 1.63 (1.07–2.48) |
| Unemployed | 73 | 68 | ||||
| Referral source | ||||||
| SEP4 | 63 | 2.57 (1.86–3.56) | 1.46 (0.96–2.20) | 57 | 2.76 (1.93–3.95) | 1.43 (0.94–2.19) |
| Other5 | 78 | 75 | ||||
| Days of heroin use in month prior to intake | -- | -- | ||||
| 0–29 days | 85 | 3.51 (2.59–4.76) | 2.81 (1.95–4.05) | - | ||
| 30 days | 65 | - | ||||
| Days of injecting heroin in month prior to intake | -- | -- | ||||
| 0 days | 86 | 2.70 (1.85–3.93) | 1.79 (1.14–2.82) | - | ||
| 1–30 days | 70 | - | ||||
| Days of cocaine use month prior to intake | ||||||
| 0–29 days | - | -- | -- | 75 | 4.19 (2.83–6.21) | 2.58 (1.61–4.13) |
| 30 days | - | 42 | ||||
| Days of IV cocaine month prior to intake | ||||||
| 0 days | - | -- | -- | 86 | 3.67 (2.45–5.49) | 3.15 (1.93–5.13) |
| 1–30 days | - | 65 | ||||
1
Unadjusted Odds Ratio
2
Adjusted for all baseline variables listed in the table
3
CI: Confidence Interval
4
SEP: Syringe Exchange Program referral source
5
Other: Referral from sources other than SEP
6
Bolded text indicates statistically significant relationship.